Daewoong saw the highest growth of 1.37% in patent filings in April and 0.74% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.37% and grants by 0.49%. GlobalData’s DataBook provides a comprehensive analysis of Daewoong’s patent filings and grants. Buy the databook here.
Daewoong has been focused on protecting inventions in South Korea(KR) with 12 publications in Q2 2024
The South Korea(KR) Patent Office dominates the patent filings and grants with nearly 24% filings and 33% grants. The World Intellectual Property Organization(WIPO), South Korea(KR), Japan(JP), and European Patent Office(EPO) patent Office are among the top ten patent offices where Daewoong is filings its patents. Among the top granted patent authorities, Daewoong has 33% of its grants in South Korea(KR), 33% in European Patent Office(EPO) and 11% in Australia(AU).
Roche could be the strongest competitor for Daewoong
Patents related to rare diseases and nanomedicine lead Daewoong's portfolio
Daewoong has the highest number of patents in rare diseases followed by, nanomedicine and climate change. For rare diseases, nearly 80% of patents were filed and no patents were granted in Q2 2024.
Fibrosis related patents lead Daewoong portfolio followed by diabetes, and endothelial dysfunction
Daewoong has highest number of patents in fibrosis followed by diabetes, endothelial dysfunction, kidney disease (nephropathy), and systemic sclerosis (scleroderma).
For comprehensive analysis of Daewoong's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.